08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
New York is joining the growing number of states that have beefed up their equal pay laws. On July 1...
Read More >
California Governor Gavin Newsom has signed numerous pro-employee bills into law that will impact al...
Read More >
Resolution 2103 of January 27, 2021, of the Superintendence of Industry and Commerce (“SIC”) sets ...
Read More >
On October 2, the SBA issued SBA Procedural Notice 5000-20057, Paycheck Protection Program Loans and...
Read More >
Concrete Contractor Fired Worker after He Complained about Assault, Federal Agency Says - BALTIMO...
Read More >
Recently, the U.S. Supreme Court granted a writ of certiorari to hear Retirement Plans Committee of ...
Read More >